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Abstract
Background: Compelling evidence exists that magnetic fields modulate living systems. To date,
however, rigorous studies have focused on identifying the molecular-level biosensor (e.g., radical
ion pairs or membranes) or on the behavior of whole animals leaving a gap in understanding how
molecular effects are translated into tissue-wide and organism-level responses. This study begins
to bridge this gulf by investigating static magnetic fields (SMF) through global mRNA profiling in
human embryonic cells coupled with software analysis to identify the affected signaling pathways.
Results: Software analysis of gene expression in cells exposed to 0.23–0.28 T SMF showed that
nine signaling networks responded to SMF; of these, detailed biochemical validation was performed
for the network linked to the inflammatory cytokine IL-6. We found the short-term (<24 h)
activation of IL-6 involved the coordinate up-regulation of toll-like receptor-4 (TLR4) with
complementary changes to NEU3 and ST3GAL5 that reduced ganglioside GM3 in a manner that
augmented the activation of TLR4 and IL-6. Loss of GM3 also provided a plausible mechanism for
the attenuation of cellular responses to SMF that occurred over longer exposure periods. Finally,
SMF-mediated responses were manifest at the cellular level as morphological changes and
biochemical markers indicative of pre-oligodendrocyte differentiation.
Conclusion: This study provides a framework describing how magnetic exposure is transduced
from a plausible molecular biosensor (lipid membranes) to cell-level responses that include
differentiation toward neural lineages. In addition, SMF provided a stimulus that uncovered new
relationships – that exist even in the absence of magnetic fields – between gangliosides, the time-
dependent regulation of IL-6 signaling by these glycosphingolipids, and the fate of embryonic cells.
Background
Life exists amid an electromagnetic background and it is
therefore not surprising that biological systems are finely
tuned to detect and react to static magnetic fields (SMF) of
various strengths. In a well known example from nature,
the migration of birds is guided by very low strength geo-
magnetic fields [1-5]. In humans, there are intriguing
reports – exemplified by an anecdotal Harvard study that
showed severely depressed manic depressive patients
experienced dramatic mood swings towards happiness
during MRI [6] and pilot pain management clinical trials
[7,8] – that magnetic fields can benefit health. In more rig-
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orously controlled animal studies, beneficial effects on
pain reduction [9], hypertension [10], wound healing
[11], inflammation [12], and microvascular circulation
[13] have been reported. To facilitate the translation of
these early results to efficacious therapeutic modalities, a
greater understanding of the underlying biological basis
of magnetic exposure is required [13]. Accordingly, in this
paper we take steps towards bridging the gap between the
established biophysical effects of magnetic fields on sub-
cellular macromolecular components and reported tissue-
level and whole organism responses by exploring whether
SMF can function as a novel stimulus for signaling path-
ways at the cell level.
The premise that SMF can modulate signaling networks is
based on reports that establish lipid bilayers as the most
compelling molecular biosensors capable of responding
to magnetic exposure. Specifically, moderate strength SMF
can change biophysical properties of membranes that
include hyperpolarization [14], redox potential [15], and
fluidity [16] thereby altering flux through sodium (Na+)
[17] and calcium (Ca2+) [13,16] channels. As a result,
changes in cytosolic concentrations of the calcium ion –
which serves as a second messenger in several signaling
pathways – occurs ubiquitously in cells exposed to SMF
[18]. In addition to altering ion channel flux, biophysical
changes to membranes may also affect lipid raft microdo-
mains in ways that modulate downstream signaling; an
example of this phenomenon is the impact of ethanol on
lipid rafts and the concomitant changes to toll like recep-
tor 4 (TLR4) activity [19]. In contrast to ethanol – which
increases membrane domain fluidity – SMF exposure
increases membrane rigidity, an effect that has been cou-
pled to the promotion of differentiation in osteoblast-like
cells [20].
In the first part this study, mRNA profiling of SMF-treated
cells coupled with analysis of the microarray data by the
Ingenuity Pathway Analysis software tool [21-23] verified
that anticipated transcriptional changes – qualitatively
consistent with the impact of altered Ca2+ flux or mem-
brane domain fluidity on signaling pathways – did occur.
Building on this finding, we conducted a detailed molec-
ular and biochemical characterization of cellular elements
linked to interleukin-6 (IL-6, which was identified to
respond to SMF from the software analysis) in human
embryonic cells. As a framework for the ensuing experi-
ments described in this study, these connections are dia-
grammed in Figure 1; this figure shows both known
connections between IL-6 and other molecular players
(e.g., Ca2+ and TLR4) as well previously unappreciated
links (e.g., ganglioside involvement in IL-6 activation that
acts even in the absence of SMF, offering a new controlling
mechanism for IL-6). This study concludes by showing
that SMF leads towards oligodendrocyte differentiation in
human embryonic cells by preferentially stimulating pre-
oligodendrocyte markers over the astrocyte markers usu-
ally associated with IL-6 exposure. Together, these results
establish SMF as an intriguing means to ultimately (and
non-invasively) stimulate cells in an endogenous niche.
Results and discussion
Transcriptional profiling and Ingenuity Pathway Software 
analysis
To gain evidence for the hypothesis that SMF exposure
activates or otherwise modulates signaling networks,
human embryoid body derived (hEBD) cells [24] were
exposed to 0.23–0.28 T fields and mRNA microarray pro-
filing was used to determine changes to global patterns of
gene expression. In the first tests, 15 min SMF exposure
(followed by one day recovery) was tested based on
reports that gene expression responded to magnetic expo-
sure this quickly [25]. In our evaluation, however, only
two genes were up- and down-regulated with a statistical
probability > 95% (Table 1) and none met the common
benchmark of a 2- (or even 1.75-) fold change. Nonethe-
less, the reproducibility over multiple probes for the same
gene indicated that these modest changes were real and
provided impetus to investigate longer term exposure.
Indeed, after one day (~24 h) of SMF treatment, 379 genes
were up-regulated and 549 were down-regulated with sta-
tistical significance (Figure 2A); even greater changes were
seen after 4 or 5 days of exposure. The magnitude of the
change for most genes, however, was modest (Figure 2B)
with only 7 showing up-regulation ≥ 2-fold (Figure 2C)
and 20 showing a similar degree of down-regulation (Fig-
ure 2D). After 5 days of continuous SMF exposure, the
number of genes up-regulated by ≥ 2-fold increased to 85
(Figure 2C) while 94 were down-regulated to a similar
extent. Interestingly, in an experiment where the cells
were allowed to recover for one day under normal culture
conditions after prolonged SMF exposure, the number of
genes that remained up-regulated by ≥ 2-fold fell by
almost half (from 85 to 47, Figure 2C) whereas the
number of down-regulated genes increased by 35 (Figure
2D).
The microarray results were consistent with the activation
of signal transduction pathways over the short term (i.e.,
in less than one day) leading to an amplified set of genetic
changes over the next several days. A simple inspection of
transcriptional changes (for example, the top 5 up- and
down-regulated genes under each exposure condition
listed in Tables 2, 3, and 4) did not lead to any obvious
insights into the over-riding effects of SMF however.
Therefore, to flesh out this hypothesis, the Ingenuity Path-
way Analysis software tool [21,26] was used to analyze the
microarray data resulting in the identification of nine net-
works that responded to SMF exposure in hEDB LVEDBMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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cells (Table 5; data analysis is shown for cells subject to
five days of continuous SMF exposure and the annotated
networks are provided in Additional file 1). Several of
these pathways reflected known biological responses to
magnetic exposure. For example, changes to intracellular
Ca2+ pools observed in cell lines exposed to SMF [18,27]
were consistent with interleukin-6 (IL-6) centered signal-
ing responses (ID#2, Table 5) mediated through the abil-
ity of this cytokine to be modulated by Ca2+ flux [28].
Similarly, Wnt responses (ID#6, Table 5) can be activated
by a non-canonical Ca2+  dependent mechanism [29].
Moving above the cell level, two networks were identified
(ID#3 and ID#5) that related to cardiovascular develop-
ment and hematological function, respectively, and thus
dovetail with a recent report by Morris and Skalak where
SMF exposure of 0.06–0.14 T for a comparable time
period (seven days) facilitated micro-vessel regeneration
after surgical intervention [13]. Likewise, Strieth and
Overview of crosstalk between SMF and IL-6 Figure 1
Overview of crosstalk between SMF and IL-6. Connections between SMF and IL-6 are shown in black, TLR4 in blue, gan-
gliosides in green, feed-forward regulation of IL-6 on itself in purple, and whole cell responses (e.g., differentiation) in orange. 
Connections supported by data collected in this work are shown by solid lines (and the location of this data in subsequent fig-
ures is provided); dotted lines show connections based on the literature, as referenced. (A) SMF exposure modulates calcium 
flux (Fig. 3C and Fig. 11A). (B) Early increases in IL-6 mRNA levels (within 2 h, Fig. 3A) occur followed by increased levels of 
secreted IL-6 (within 7 h, Fig. 3B). (C) Likewise, SMF activates TLR4 (Fig. 3D), resulting in (D) feed-forward self-stimulation 
[41]. (E) In turn, TLR4 leads to IL-6 activation either through (F) a reported Ca2+-dependent route [39] or (G) through 
changes to p38 phosphorylation (Fig. 4A) that (H) transiently hinder proliferation in hEBD LVEC cells (Fig. 4B) without leading 
to apoptosis (Fig. 4C& D). SMF also has early-acting effects on NEU3 (I) and ST3GAL5 (J) mRNA levels (Fig. 8F) with (K) a 
concomitant decrease in ganglioside levels (Fig. 8B&C). (L) In the absence of SMF, exogenously-added ganglioside GM3 sup-
presses IL-6 production (Fig. 6A) and (M) TLR4 [38]. (N) IL-6 reduces ganglioside levels (Fig. 6B) through changes to (O) 
NEU3 and (P) ST3GAL5 mRNA levels (Fig. 7D) that (R) involve ERK1/2 phosphorylation (Fig. 7B&C). 'Downstream' responses 
to the combined administration of (S) IL-6 and (T) SMF include reproducible changes in cell morphology (Fig. 9E) and biochem-
ical markers consistent with pre-oligodendrocyte differentiation (Fig. 10).BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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coauthors have reported that SMF affects the vascular and
blood flow [30] and Okano and coworkers have investi-
gated the modulation of blood vessels by magnetic fields
[10,31-33].
SMF increased IL-6 mRNA levels and protein secretion at 
early time points
Even though the software analysis of the microarray data
was consistent with a mechanism wherein SMF acted as a
stimulus for signaling pathways, limitations of this meth-
odology precluded any firm conclusions. Signaling path-
way responses, for example, are typically measured over
time intervals of minutes to hours and require evaluation
with closely-spaced time points not practical by microar-
ray profiling over several days. Therefore, to verify that the
transcriptional changes we observed represented legiti-
mate responses to SMF, we selected IL-6 for conventional
biochemical characterization. Of the nine networks iden-
tified by microarray profiling, the selection of IL-6 for
additional scrutiny was based on several factors. First, a
recent report linked 0.4 T SMF exposure to increased IL-6
production in fibroblasts [34] and plausible membrane-
based modes of activation IL-6 (e.g., through Ca2+ or
TLR4) exist. Furthermore, reports that SMF can promote
differentiation [20] – coupled with the propensity of the
hEBD LVEC line used in this study to display neural mark-
ers [24] together with reports that IL-6 promotes astrocy-
togenesis [35] – offered the possibility that cell-level
responses (e.g., differentiation of the hEBD cells to astro-
cytes) could be observed in these experiments.
Biochemical validation began by quantitative real-time
polymerase chain reaction (qRT-PCR) analysis of IL-6
mRNA levels over the first 24 h of SMF exposure, a time
frame selected based on the numerous changes seen in the
microarray data after one day (Figure 2) and literature
reports of biphasic IL-6 activation during this time period
[36]. In these experiments, IL-6 mRNA levels increased
two hours into SMF exposure and remained elevated com-
pared to untreated control cells at 4, 7 and 24 h (Figure
3A). IL-6 secretion into the culture medium followed
slower kinetics, first showing a measurable increase at 7 h
after which SMF-treated cells out-produced control cells
up to 96 h (Figure 3B). The SMF-exposed cells experienced
the largest relative increase compared to untreated con-
trols at 48 h, followed by a decline to slightly less than
control levels at the end of the six day monitoring period.
TLR4 was activated by SMF in tandem with IL-6
Upon verifying that IL-6 was activated by SMF at both the
mRNA and protein levels, we sought more detailed
insight into this response. As indicated in Figure 1A &1B
(for perspective, Figure 1 summarizes the connections
between SMF, IL-6 and other pathways elements and cel-
lular outcomes described in this report), IL-6 activation
was consistent with the known ability of magnetic fields
to alter calcium ion channel flux and reports of Ca2+-
dependent up-regulation of IL-6 (the impact of SMF on
calcium flux was experimentally verified for currently-
used hEBD LVEC cells, Figure 3C). In addition, connec-
tions IL-6 shares with TLR4 [37-39], combined with the
dependence of the signaling activity of Toll-like receptors
on their lateral diffusion within membrane microdo-
mains [19,40], suggested a parallel route through which
SMF could influence IL-6. Specifically, a sequence of
events can be postulated where SMF changes membrane
fluidity thereby modulating TLR4 (Figure 1C) and down-
stream IL-6 responses (Figure 1E) through a Ca2+-depend-
ent mechanism (Figure 1F) or through TLR4-mediated
p38 phosphorylation (Figure 1G).
Experimentally, because TLR4 transcription is strictly
auto-regulated in a stimulus-dependent manner ([38,41]
and Figure 1D), qRT-PCR can be used to monitor its acti-
Table 1: Microarray profiling of mRNA levels in hEBD cells exposed to SMF for 15 min.
Affy Probeset ID Gene Title Gene Symbol Ratio Average Signals
(+ or -) fold-regulation Control Experimental
Up-regulated genes:
209189_at v-fos FBJ murine osteosarcoma viral oncogene 
homolog
FOS (+) 1.59 105.4 168.0
1562836_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 DDX6 (+) 1.59 226.5 359.8
205195_at adaptor-related protein complex 1, sigma 1 subunit AP1S1 (+) 1.48 212.1 314.4
219730_at mediator of RNA polymerase II transcription, 
subunit 18 homolog (yeast)
MED18 (+) 1.47 20.3 29.7
209189_at v-fos FBJ murine osteosarcoma viral oncogene 
homolog
FOS (+) 1.59 105.4 168.0
Down-regulated genes:
AFFX-BioB-3_at Biotin synthase///biotin synthesis, sulfur insertion bioB (-) 1.70 422.5 275.5
AFFX-r2-Ec-bioC-5_at Biotin synthesis protein bioC///biotin biosynthesis; 
reaction prior to pimeloyl CoA
bioC (-) 1.62 1185.5 732.7
AFFX-BioDn-5_at dethiobiotin synthetase bioD (-) 1.52 1181.8 734.2BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
Page 5 of 23
(page number not for citation purposes)
mRNA profiling of SMF-treated hEBD cells Figure 2
mRNA profiling of SMF-treated hEBD cells. (A) The magnitude and number of genes that showed statistically significant 
changes in mRNA levels after SMF exposure compared to untreated control cells are given (four data points, representing 
genes with ≥ 5-fold changes in mRNA levels are not indicated in (A) but are shown in the expanded view of the 50 highest up- 
and down-regulated genes provided in (B); the "missing" genes are listed in Tables 2–4). Venn diagrams depicting the number 
of genes up- or down-regulated by ≥ 2-fold compared to cells continuously incubated under normal culture conditions are 
shown in Panels C and D, respectively. Note that the "1 day SMF" designation refers to the Group 2 treatment conditions 
described in the Methods section, (the greatest up- and down-regulated genes are listed in Table 2); "5 days SMF" refers to 
Group 3 cells (Table 3); and "w/1 day recovery" refers to Group 4 cells (Table 4); in all cases comparison is made to Group 
1 control cells that were not exposed to SMF.BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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vation. By monitoring this endpoint, we found that TLR4
transcript levels increased during the first several hours of
SMF exposure (Figure 3D). Interestingly, self-activation of
TLR4 can lead to either the down-regulation of its mRNA
(as seen in rat glial [38] or murine macrophages [42]) or
to up-regulation (as seen in murine lung [37] or human
monocytes and polymorphonuclear leukocytes [43]); the
current up-regulation of TLR4 mRNA observed in SMF-
treated embryonic cells is consistent with results obtained
in other types of human cells upon activation of TLRs.
SMF activation of TLR4 impinges upon MAPK pathways
The activation of IL-6 in cells exposed to SMF was consist-
ent with signal transduction through the upstream
involvement of TLR4 (Figure 1E&1G). To gain biochemi-
cal evidence for this connection, we analyzed the phos-
phorylation of p38, which lies in the pathway that
connects TLR4 with IL-6, and found the predicted increase
in phosphorylated p38 in SMF treated cells (Figure 4A).
This result, in addition to establishing a connection
between IL-6 and SMF through TLR4, provided evidence
that SMF impinges on MAPK signaling (p38 plays a cen-
tral role in mediating MAPK responses) prompting us to
evaluate changes to proliferation and apoptosis. In these
experiments a significant reduction in proliferation was
seen for hEBD LVEC cells after three days of SMF expo-
sure; this effect lessened by the sixth day and was lost by
the ninth day (Figure 4B). Qualitatively, this short term
change in proliferation was consistent with studies where
SMF transiently altered proliferation [44]. Annexin/pro-
pidium iodide staining assays showed that reduced prolif-
eration during early phases of SMF exposure was not a
Table 2: Gene expression for hEBD LVEC cells exposed to SMF for one day (i.e., "Group 2") compared to control cells incubated 
without SMF exposure (Group 1).
Affymetrix Probeset ID Gene Designation Gene Symbol Ratio Average Signals
(+ or -) fold-regulation Control Experimental
Up-regulated genes:
1554452_a_at hypoxia-inducible protein 2 HIG2 (+) 2.41 328.9 792.0
230746_s_at Stanniocalcin 1 STC1 (+) 2.40 1035.7 2483.9
218149_s_at zinc finger protein 395 ZNF395 (+) 2.08 349.4 725.9
218507_at hypoxia-inducible protein 2 HIG2 (+) 2.08 391.7 813.4
223216_x_at zinc finger protein 395///F-box protein 16 ZNF395///FBXO16 (+) 2.05 241.7 495.4
Down-regulated genes:
217967_s_at chromosome 1 open reading frame 24 C1orf24 (-) 3.34 848.5 254.0
205569_at lysosomal-associated membrane protein 3 LAMP3 (-) 3.01 186.3 61.9
229778_at Hypothetical protein MGC10946 (-) 2.74 159.6 58.3
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 (-) 2.52 611.4 242.4
220892_s_at phosphoserine aminotransferase 1 PSAT1 (-) 2.42 2701.91 1116.08
205207_at interleukin 6 (interferon, beta 2) IL6 (-) 1.93 266.3
Table 3: Gene expression for hEBD LVEC cells exposed to SMF for five days (i.e., Group 3) compared to control cells incubated 
without SMF exposure (Group 1).
Affymetrix Probeset ID Gene Designation Gene Symbol Ratio Average Signals
(+ or -) fold-regulation Control Experimental
Up-regulated genes:
242517_at G protein-coupled receptor 54 GPR54 (+) 7.84 60.1 470.7
1554452_a_at hypoxia-i hypoxia-inducible protein 2nducible 
protein 2
HIG2 (+) 4.40 328.9 1446.4
205493_s_at dihydropyrimidinase-like 4 DPYSL4 (+) 4.17 184.1 767.3
226682_at hypothetical protein LOC283666 (+) 3.91 391.7 1530.5
226431_at amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 13
ALS2CR13 (+) 3.79 80.9 306.4
232068_s_at toll-like receptor 4 TLR4 (+) 1.58 195.4 309.5
Down-regulated genes:
217967_s_at chromosome 1 open reading frame 24 C1orf24 (-) 7.60 848.5 111.7
220892_s_at phosphoserine aminotransferase 1 PSAT1 (-) 4.72 2701.9 572.5
205047_s_at asparagine synthetase ASNS (-) 4.64 2327.5 501.5
210587_at inhibin, beta E INHBE (-) 4.12 176.6 42.8
204475_at matrix metallopeptidase 1 
(interstitial collagenase)
MMP1 (-) 3.98 112.8 28.3
205207_at interleukin 6 (interferon, beta 2) IL-6 (-) 3.23 513.2 158.9BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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consequence of increased apoptosis (Figure 4C&4D) in
agreement with reports that SMF, if anything, is protective
against apoptosis [18,45]. Having ruled out that the SMF
treated cells were dying, a plausible explanation for the
reduced proliferation was that the cells were undergoing
differentiation with a concomitant decrease in their
growth rate; this possibility was supported by data pre-
sented later in this report.
SMF responses are cell line dependent
As a brief diversion from the main thrust of this study,
which was to connect SMF with cellular responses associ-
ated with IL-6 in human embryonic cells, we wish to
emphasize that the impact of SMF on other common lab-
oratory cells such as the Jurkat, HeLa, and HEK AD293
lines was surveyed and "obvious" effects such as pro-
nounced changes in proliferation (as seen in Figure 4B for
the hEBD LVEC line) or altered morphology (as shown
later in this report) were not observed. For example, rep-
resentative data is shown for the HEK AD293 line in Fig-
ure 5 where control and SMF-exposed cells had identical
growth rates when measured by either the MTT assay
(Panel A) or through cell counting (Panel B). The clear-cut
differences seen between the embryonic hEBD LVEC line
and cancer lines were not surprising based on reports that
even closely-matched cell lines respond uniquely to SMF
[46]; instead these findings support the hypothesis that
changes to Ca2+ flux (as shown in Figure 3C) – a parame-
ter that is highly cell line dependent [18] – contributes to
the cellular responses we observed in the cells exposed to
SMF.
Connections between gangliosides and IL-6 exist in hEBD 
LVEC cells
To gain insight into whether regulatory networks beyond
TLR4 or calcium flux contributed to the up-regulation of
IL-6 in SMF treated cells, we next focused on gangliosides
[38,47]. Gangliosides are sialic acid-bearing glycosphin-
golipids (GSLs) that are integral components of lipid rafts
and caveolae of the type surrounding TLR4 that not only
organize these microdomains but also regulate the signal-
ing functions of embedded proteins (as discussed in more
Table 4: Gene expression for hEBD LVEC cells exposed to SMF for four days followed by one day of recovery (i.e., Group 4) compared 
to cells incubated without SMF exposure (Group 1).
Affymetrix Probeset ID Gene Designation Gene Symbol Ratio Average Signals
(+ or -) fold-regulation Control Experimental
Up-regulated genes:
242517_at G protein-coupled receptor 54 GPR54 (+) 5.16 60.1 310.0
205200_at C-type lectin domain family 3, member B CLEC3B (+) 3.28 111.1 364.7
205493_s_at dihydropyrimidinase-like 4 DPYSL4 (+) 3.27 184.1 601.7
218149_s_at zinc finger protein 395 ZNF395 (+) 2.96 409.4 1212.0
1554452_a_at hypoxia-inducible protein 2 HIG2 (+) 2.90 328.9 955.0
232068_s_at toll-like receptor 4 TLR4 (+) 1.36 195.4 266.5
Down-regulated genes:
217967_s_at chromosome 1 open reading frame 24 C1orf24 (-) 8.90 848.5 95.3
205047_s_at asparagine synthetase ASNS (-) 4.95 2327.5 470.0
223062_s_at phosphoserine aminotransferase 1 PSAT1 (-) 4.84 3784.5 781.5
210587_at inhibin, beta E INHBE (-) 3.96 176.6 44.6
229778_at Hypothetical protein MGC10946 (-) 3.95 159.6 40.5
205207_at interleukin 6 (interferon, beta 2) IL6 (-) 3.16 513.2 162.4
Table 5: Signaling networks identified to respond to SMF exposure through data analysis with the Ingenuity Pathway Analysis software 
tool.1
ID # Signaling Network Title
1 Lipid Metabolism, Small Molecule Biochemistry, Drug Metabolism
2 Metabolic Disease, Cellular Development, Connective Tissue Development and Function
3 Cardiovascular System Development and Function, Cellular Development, Cellular Growth and Proliferation
4 Cell Cycle, Organ Morphology, Connective Tissue Development and Function
5 Cellular Movement, Cell-To-Cell Signaling and Interaction, Hematological System Development and Function
6 Cell Death, Neurological Disease, Cellular Function and Maintenance
7 Lipid Metabolism, Small Molecule Biochemistry, Metabolic Disease
8 Carbohydrate Metabolism, Molecular Transport, Small Molecule Biochemistry
9 Cell Cycle, Cancer, Cellular Growth and Proliferation
1 Annotated network diagrams are provided in Additional file 1.BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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detail in review articles [48,49]). Consequently, TLR4 [38]
and IL-6 [47] can be influenced by the equilibrium
between the 'inert' (in this context) GSL lactosylceramide
(LacCer) and the suppressive ganglioside GM3 (Figure
1K).
Before beginning experiments to probe the impact of SMF
exposure on gangliosides, the relationship between GM3
(and its disialylated derivative GD3) and IL-6 was first
investigated to establish a baseline for the hEBD LVEC
line (before the current study, there was negligible litera-
ture precedent for a connection between GSL and IL-6 in
human embryonic cells). A long-lasting and substantial
(e.g., > 95% at 4 d) reduction in IL-6 mRNA was observed
in cells incubated with exogenously-added GM3 or GD3
(Figure 6A). Crosstalk between gangliosides and IL-6 also
held in the reverse direction as demonstrated by a dose
dependent decrease in GM3 in cells incubated with exog-
Response of interleukin-6 (IL-6) to SMF exposure and putative activating mechanisms in hEBD LVEC cells Figure 3
Response of interleukin-6 (IL-6) to SMF exposure and putative activating mechanisms in hEBD LVEC cells. (A) 
Levels of IL-6 mRNA were determined by qRT-PCR during the first 24 h of SMF exposure. (B) IL-6 concentrations in the cul-
ture medium of SMF-exposed and control cells were determined by ELISA at the indicated times. (C) Levels of extracellular 
and intracellular calcium after four hours of SMF exposure show the expected reciprocal relationship (a time course for extra-
cellular calcium is shown in Figure 11A). (D) Levels of TLR4 mRNA were determined by qRT-PCR during the first 24 h of SMF 
exposure. In all cases the data shown represents three or more independent experiments (denoted as n ≥ 3 in subsequent fig-
ure legends) and error bars represent standard (SD); in Panels A, C, and D, p < 0.05 for all data points shown that compare 
SMF-treated and control cells; in Panel B, "*" indicates p < 0.05 and "**" indicates p < 0.01 (in this figure, and throughout this 
study, statistical significance was determined by the Student t-test and differences were considered to be significant when p < 
0.05 (or p < 0.01 when specifically indicated)).
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MAPK-related responses to SMF in hEBD LVEC cells Figure 4
MAPK-related responses to SMF in hEBD LVEC cells. (A) An increase in p38 phosphorylation occurred in the SMF-
treated cells (representative results from one of three experiments is shown for 30 min of SMF exposure; a normalized ratio of 
phosphorylated p38 (Ph-p38) to p38 is provided in the bar graph after quantification of the western blots by densitometry). (B) 
Proliferation of SMF-exposed cells decreased over the first 6 days of SMF exposure but not at nine days (error bars represent 
SD for n ≥ 3 independent experiments and "*" indicates p < 0.05 and "**" indicates p < 0.01). No change in the number of 
apoptotic cells was detected after SMF exposure when evaluated by the Annexin V/propidium iodide assay (Panel C; repre-
sentative data from one of three experiments is shown) compared to control cells (Panel D).
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enously-added IL-6 (Figure 6B). By reducing the amount
of GM3 present in a cell (Figure 1N), IL-6 can alleviate the
suppressive effects of this ganglioside on its transcription
(Figure 1L) thus setting up a 'feed-forward' loop that offers
an mechanistic explanation for the self-activation of IL-6
described in the literature [50] and demonstrated for
hEBD LVEC cells in this study (Figure 6C). Figure 6C
shows that levels of TLR4 mRNA also increased signifi-
cantly in IL-6 supplemented cells consistent with the
removal of concomitant inhibitory effects of GM3 on
TLR4 [38]. Together with the impact of SMF on IL-6
shown in Figure 3, these results demonstrate that SMF has
the capacity for tuning IL-6 signaling by adjusting the rel-
ative proportions of the 'active' ganglioside GM3 and its
'inert' asialo counterpart LacCer (Figure 1K) thereby con-
tributing to the transcriptional up-regulation of TLR4 and
IL-6 (Figure 1M&1N).
IL-6 mediated changes to GM3 and GD3 occur via NEU3 
and STGAL5
Mechanistically, changes to one of two enzymes could
explain the shift in equilibrium away from the suppressive
ganglioside GM3 to its inert asialo counterpart LacCer
(Figure 1K); specifically, an increase in the recycling
enzyme NEU3 or a decrease in the biosynthetic enzyme
ST3GAL5 (Figure 7A). Despite no previously-known
direct links between IL-6 and ST3GAL5 or NEU3,
increased phosphorylation of ERK1/2 has been connected
with the up-regulation of STGAL5 ([51], as shown in Fig-
ure 1P). Therefore, based on a report linking IL-6 and
MAPK signaling through JAK/STAT that involved ERK1/2
(Figure 1R) [52], we reasoned that ERK1/2 could serve as
an intermediary to connect IL-6 with ST3GAL5 expres-
sion. Accordingly, we tested the phosphorylation of ERK
(Figure 7B) and found that pERK1/2 was inhibited by
concentrations of IL-6 > 4.0 ng/ml (Figure 7C); the
reduced ratio of pERK1/2 to ERK was consistent with
dampened mRNA levels for the biosynthetic enzyme
ST3GAL5 and the tandem up-regulation of the recycling
enzyme NEU3 (Figure 7D). A noteworthy aspect of this
study was that, although the effects of NEU3 and
ST3GAL5 on "lubricating signaling pathways" [49] have
been previously evaluated separately, to our knowledge
this is the first report where both enzymes were moni-
tored simultaneously and found to respond to an external
stimulus in a concerted manner that required transcrip-
tional regulation of the biosynthetic and recycling
enzymes in opposite directions.
The prolonged down-regulation of ganglioside GM3
upon IL-6 supplementation (Figure 6A) provides a two-
pronged mechanistic explanation for long term attenua-
tion of IL-6 and related responses in SMF-treated cells (for
example, SMF-enhanced IL-6 levels returned to normal by
day 6 (Figure 3B) followed by loss of growth inhibition by
day 9 (Figure 4B)). First, the loss of sialic acid – an impor-
tant contributor to the carbohydrate-carbohydrate bind-
ing interactions that stabilize lipid assemblies [48] – from
GM3 can destabilize CD82-enriched microdomains [53].
Assuming that the TLR4 receptor complex, which is also
sensitive to the stability of its local microdomain environ-
ment [19], responds to a reduction in GM3 levels in a sim-
ilar manner, the signaling pathways activated by SMF over
the first day or so of exposure could be 'turned off' by the
loss of GM3 over longer time periods. A second mecha-
nism to explain ganglioside-mediated attenuation of IL-6
can be postulated based on the findings by Müthing and
colleagues that GSL such as GM3 increase Ca2+  flux
through voltage gated channels [54]. In an independent
Proliferation is not altered by SMF in HEK AD293 cells Figure 5
Proliferation is not altered by SMF in HEK AD293 
cells. The cell line dependence of SMF effects is illustrated by 
the lack of a response in SMF-treated HEK AD293 cells when 
proliferation was measured by the MTT assay (Panel A) or 
by cell counts (Panel B). Error bars represent SD for n ≥ 3 
independent experiments and in all cases p > 0.05.
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Crosstalk between IL-6 and gangliosides in hEBD LVEC cells Figure 6
Crosstalk between IL-6 and gangliosides in hEBD LVEC cells. (A) IL-6 mRNA decreased upon supplementation of the 
culture medium with 5.0 μM of either GM3 or GD3 (n ≥ 3; p < 0.01 for all time points shown compared with controls that 
were incubated in the absence of IL-6). (B) Ganglioside GM3 decreased in a dose-dependent manner in cells supplemented 
with 1.0 or 4.0 ng/ml IL-6 for 24 h. (C) mRNA levels for IL-6 and TLR-4 increased in cells incubated with IL-6 (error bars rep-
resent SD for n ≥ 3 independent experiments and p < 0.05 for both measurements).
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Ganglioside metabolism and connections with ERK1/2 Figure 7
Ganglioside metabolism and connections with ERK1/2. (A) This diagram shows the conversion of LacCer to the gan-
glioside GM3 by ST3GAL5 (and then to GD3 upon α-2,8-sialylation and to 9-O-AcGD3 upon O-acetylation); both GM3 and 
GD3 are converted back to LacCer by NEU3. (B) Western blots of ERK1/2 and pERK1/2 from control and IL-6-treated hEBD 
LVEC cells (for 30 min) show reduced ERK1/2 phosphorylation at concentrations > 4 ng/ml (as quantified by densitometry and 
shown as a ratio of pERK1/2 to ERK in Panel C). (D) IL-6 treated cells exhibited increased levels of NEU3 mRNA and 
decreased levels of ST3GAL5 mRNA after 24 h (error bars represent SD for n ≥ 3 independent experiments and p < 0.05 for 
both data sets).
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set of experiments, Yang and coworkers reported a
strongly stimulatory effect for GM3 on the SR Ca2+-ATPase
[55-58]. Together, these findings indicate that the conver-
sion of GM3 to LacCer in SMF-treated cells inhibits Ca2+-
dependent signaling pathways in a manner that attenu-
ates the initial multi-pronged up-regulation of IL-6.
SMF regulates ganglioside production via NEU3 and 
ST3GAL5
The crosstalk between gangliosides and IL-6 (as summa-
rized in Figures 1L&1N and 7A), combined with the abil-
ity of SMF to modulate this cytokine (as shown by the
data in Figure 3), led us to consider whether SMF altered
IL-6 via a ganglioside-mediated route (or vice versa). To
investigate this possibility, NEU3 and ST3GAL5 – the
enzymes that control the equilibrium between GM3 and
LacCer (Figure 7A) and thus have the potential to indi-
Effects of SMF on gangliosides GM3 and GD3 and IL-6 Figure 8
Effects of SMF on gangliosides GM3 and GD3 and IL-6. (A) mRNA levels increased for NEU3 and decreased for 
ST3GAL3 during the first 24 hours of SMF exposure consistent with a flow cytometry-measured reduction in GM3 (Panel B) 
and GD3/9-O-AcGD3 levels (the antibody used recognized both the 9-O-acetylated and hydroxyl forms of GD3, Panel C). (D) 
Data from three independent flow cytometry experiments are summarized; GM3 or GD3 levels are given as measured in the 
arbitrary units shown on the x-axis of Panels B and C. (E) IL-6, which led to a decrease in ganglioside levels in naïve cells (see 
Figure 6A) had no further effect on GM3 levels (or GD3 levels, not shown) in SMF-treated cells. (F) A time course of NEU3 
and ST3GAL5 shows up- or down-regulation, respectively, over time points shorter than 24 h. Error bars for Panels A, D, and 
F represent SD for n ≥ 3 independent experiments and p < 0.05 for all data points that compare SMF-treated samples with the 
matched untreated controls.
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rectly modulate IL-6 (Figure 1L&1N) – were monitored by
qRT-PCR during the early stages of SMF exposure. In these
experiments, up-regulation of NEU3 and inhibition of
ST3GAL5 after one day of SMF exposure (Figure 8A) rem-
iniscent of the effects of IL-6 supplementation (Figure 7D)
were observed. Analysis of ganglioside levels in these cells
showed that these transcriptional changes again worked
in concert to decrease GM3 levels on the cell surface (Fig-
ure 8B, top). A similar reduction in GM3 occurred in fixed
and permeabilized cells where gangliosides situated in the
secretory pathway are also measured (Figure 8B, bottom).
By testing both conditions, the possibility that surface
changes merely reflected the redistribution of GM3
between the cell surface and intracellular compartments
was discounted (this concern was raised by the hypothesis
that SMF changes the biophysical properties of lipid bilay-
ers thereby potentially affecting trafficking between sur-
face and intracellular membranes). Interestingly, GD3 –
which can modulate the biophysical properties of mem-
brane raft assemblies similar to GM3 (and in essence
serves as a reservoir for this monosialylated ganglioside,
Figure 7A) – was also reduced by SMF (Figure 8C); this
result can be explained by the ability of NEU3 to remove
both sialic acid residues of GD3.
SMF regulates NEU3 and ST3GAL5 independently of IL-6
In order to gain insight into the cause and effect relation-
ships that connect SMF, gangliosides, and IL-6, IL-6 was
added to cells in the presence or absence of SMF. In this
experiment IL-6 had the same effect on GM3 levels with or
without concomitant magnetic exposure (Figure 8E). This
result contrasted with the clear reduction in GM3 when
IL-6 had been added to cells in the absence of SMF (as
shown in Figure 6A). One explanation for these disparate
results was that SMF activated a sequence of events where
IL-6 transcription was first up-regulated leading to
increased protein secretion, which in turn reduced GM3.
This scenario, however, was discounted by a time course
of NEU3 and ST3GAL5 mRNA expression over the first
day of SMF exposure (Figure 8F) that showed that the
transcriptional changes to these enzymes occurred before
measurable IL-6 secretion took place (e.g., before 7 h, see
Figure 3B). Therefore, SMF independently  regulates IL-6
and gangliosides in a way that ultimately impinges on the
same molecular mechanism (i.e., through NEU3 and
ST3GAL5 transcription and activity). GM3 and GD3 also
provide a putative explanation for the biphasic increase in
IL-6 mRNA; at early time points a ganglioside-independ-
ent sequence of events (presumably involving, but not
necessarily limited to, TLR4 activation or Ca2+  flux)
occurs. As the initial signal fades, reduction of GM3 and
GD3 could contribute to a second 'burst' of IL-6 expres-
sion by alleviating the suppressive effects of these ganglio-
sides on IL-6 itself (Figure 1L) or on TLR4 (Figure 1M).
SMF – in combination with IL-6 – alters cell morphology
As described earlier, hEBD LVEC cells exposed to SMF
experienced reduced proliferation without toxicity (Figure
4), a response consistent with differentiation. To test if
this phenomenon was linked to SMF or IL-6 production,
cells were first treated with ≤ 4.0 ng/ml of IL-6 in the
absence of SMF. IL-6 supplementation typically resulted
in relatively minor (if any) change to cell morphology
(Figure 9A&9B). Occasionally, however, dendrite-like
outgrowths reminiscent of neuronal cells developed in
sub-populations of IL-6 treated cells (Panel C). By con-
trast, close to 100% of the cells attained distinctive mor-
phology when SMF was combined with 4.0 ng/ml of IL-6
(Panel E; SMF alone had a much less pronounced impact
on morphology, Panel D).
One explanation for why both SMF and exogenous IL-6
supplementation was needed to elicit noticeable changes
to cell morphology was that, because of the relatively
small volume of cells (≤ 0.01%) compared to culture
medium, any IL-6 secreted in response to SMF would be
diluted ~10,000-fold. As a consequence, additional IL-6
supplementation was required to mimic levels achieved
by comparable rates of IL-6 production in cells situated
within an in vivo niche where the relative cell to interstitial
volume ratios are much lower. Another (non-exclusive)
explanation, supported by experiments where even 20 ng/
ml IL-6 could not reproduce the combined effects of SMF
plus 4 ng/ml IL-6 (data not shown), was that SMF-acti-
vated networks beyond IL-6 – such as those listed in Table
5 – contributed to the morphological changes.
SMF promotes oligodendrocyte progenitor markers
To gain greater insight into the morphological changes
induced in hEBD LVED cells by a combination of SMF
and IL-6, we noted that IL-6 has a role in the regeneration
of nervous tissue, usually promoting astrocyte formation
[35] and, accordingly, monitored the transcription of
bone morphogenic protein 2 (BMP-2) and myelin basic
protein (MBP) (Figure 9F). Interestingly, a decrease in
mRNA for BMP-2, a protein that stimulates astrocytogen-
esis [59], was observed suggesting that the hEBD cells
were not differentiating into astrocytes as expected. To
confirm this observation using immunofluorescent
microscopy, no increase in the GFAP marker associated
with astrocyte formation was observed in SMF and IL-6
treated cells (Figure 10A). Similarly, no increase was seen
for NEF (Figure 10B), a marker associated with neuron
differentiation.
Based on the lack of astrocyte or neuron differentiation, a
third possibility was that the decrease in BMP-2 expres-
sion in SMF-treated cells removed the obstacle presented
by bone morphogenetic proteins towards differentiation
to oligodendrocyte lineages [60]. Indeed, consistent withBMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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the decrease in BMP-2, an increase in myelin basic protein
(MBP) transcription was observed (Figure 9F) providing a
biochemical marker consistent with differentiation to an
oligodendrocytes [61]. Additional supporting evidence
that SMF, combined with IL-6, leads toward oligodendro-
cyte progenitor formation was provided by the increased
expression of vimentim (Figure 10C) and Gal-C (Figure
10D).
A timeline of SMF responses: Towards unraveling cause 
and effect relationships
The relationships between SMF, calcium, TLR4, ganglio-
sides (and regulatory enzymes), MAPK pathway elements
(p38 and ERK1/2) and IL-6 are outlined in Figure 1; this
diagram, however, does not provide a dynamic view that
would provide insight into cause and effect relationships.
Therefore, to summarize the time dependence of various
aspects of hEBD LVEC cell responses to SMF exposure,
early, intermediate, and longer term responses are sum-
marized in Figure 11. During the first four hours (Panel
A), changes to calcium flux occur within minutes as do
MAPK responses (e.g., p38 phosphorylation, Figure 4A);
effects on the transcription of IL-6, TLR4, NEU3, and
ST3GAL5 mRNA lag slightly but show a strong response
beginning between 2 and 4 hours. By contrast, secreted IL-
6 remains unchanged. During the remainder of the first
day of exposure (Panel B), mRNA levels of SMF treated
cells trend back to control levels (the one exception is the
24 hour point for IL-6, which rebounds after a decline
between 4 and 7 hours, this biphasic response mimics the
impact of other stimuli on IL-6 [36]). Also during the first
day, while the impact of SMF on transcription of IL-6,
TLR4, NEU3, and ST3GAL5 abates, phenotypic effects
such as the accumulation of measurable levels of secreted
IL-6 began to be manifest. In general, initiating events –
for example, the impact of SMF on mRNA levels – were
attenuated after the second day (as shown in Panel C)
whereas "behavioral" responses (such as the secretion of
IL-6 or the effects of SMF on proliferation) followed the
same trend but lagged in time. During this multiday time
period – while "intermediate" responses were returning to
normal – long-lived changes to cell fate arose that
included the morphological changes shown in Figure 9
and the accumulation of pre-oligodendrocyte markers
shown in Figure 10.
Another lesson learned from the data shown in Figure 11
was that SMF treatment set in motion a complex sequence
Morphological effects of SMF and IL-6 on hEBD LVEC cells Figure 9
Morphological effects of SMF and IL-6 on hEBD LVEC cells. (A) Phase contrast images showing the normal morphol-
ogy of ~90% confluent hEBD LVEC cells. (B) Slightly altered morphology typically was seen after incubating the cells with 4.0 
ng/ml of IL-6 for 3 days. (C) Cells incubated with 4.0 ng/ml IL-6 sporadically attained dramatically altered cell morphology, with 
neurite-like outgrowths. (D) SMF, by itself, had a minor impact on the morphology of hEBD LVEC cells. (E) The combination 
of SMF and 4.0 ng/ml IL-6 resulted in ~100% of the cells attaining the distinctively altered morphology shown. (F) mRNA levels 
of bone morphogenetic protein 2 (BMP2), myelin basic protein (MBP), and IL-6 after 24 h of SMF exposure (error bars repre-
sent SD for n ≥ 3 independent experiments and p < 0.05 for each marker).BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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of events that rapidly changed over time; consequently,
the original goal of analyzing cellular responses by micro-
array profiling could have led to erroneous conclusions.
For example, the complex and rapidly changing nature of
IL-6 mRNA transcription could have led to the conclusion
that the microarray results were simply irreproducible, as
has been reported for much lower-strength fields [62].
Alternately, the four and five day time points – where IL-
6 mRNA levels were actually lower than controls – were
not consistent with the strong, multifaceted up-regulation
that occurred upon the initial exposure to magnetic stim-
ulus thereby also providing misleading information if
regarded in isolation. Therefore, we close by noting the
benefits of the robust ability of software tools to uncover
signature biological activity – namely, signaling responses
associated with IL-6 – even when the key molecular player
(i.e., IL-6) is undergoing rapidly changing or oscillatory
behavior that would be difficult to understand by itself.
Conclusion
At the outset, we emphasize that this study was not
intended to provide a comprehensive account of the cel-
lular effects of SMF. For example, mechanisms other than
those based on a lipid biolayer 'biosensor' may contribute
to the transcriptional changes observed in this study as
direct effects of SMF on protein-DNA interactions have
been postulated [63-66] as have changes in enzymatic and
biochemical reactions [5,67-69]. Therefore, we reiterate
that our goal was to provide a rudimentary framework of
one of many parallel or complementary mechanisms
through which magnetic stimuli are transduced from
molecular level biosensors into cell-level responses. This
objective was pursued by mRNA microarray profiling that
verified time-dependent global changes in transcription
occurred that were consistent with the activation of sign-
aling pathways. Then, to gain insight into the specific net-
works affected by SMF exposure, which were not obvious
by simple inspection of the genes involved, the microar-
ray data was subject to software analysis and signaling net-
works consistent with tissue- or organ-level responses to
Differentiation markers in SMF- and IL-6-treated hEBD LVEC cells Figure 10
Differentiation markers in SMF- and IL-6-treated hEBD LVEC cells. Test cells were incubated with 4.0 ng/ml IL-6 
with concurrent SMF exposure (controls were incubated with neither) and the monolayers were co-stained with Oregon 
Green 488 phalloidin to visualize actin, the nuclear dye DAPI (blue), and one of the following markers (red): (A) the astrocyte 
marker GFAP (note that the lack of staining indicates the absence of this marker in both treated and control cells); (B) the 
neuron marker NEF; and the pre-oligodendrocyte markers (C) Vim and (D) Gal-C. Images were obtained by confocal micros-
copy using identical exposure settings for each set of photographs.BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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magnetic exposure (that include benefits to wound heal-
ing [11] and inflammation [12]; cardiovascular effects
[13] such as modulation of blood flow and pressure [10];
and anti-tumor activity [70,71]) were identified.
Although the microarray data identified cellular responses
consistent with previously reported biological responses
to magnetic exposure, we nonetheless sought to ensure
that these associations were not just coincidental or an
artefact of the software analysis. Detailed biochemical
investigation of all nine pathways (see Table 5) was well
beyond the scope of a single study, therefore we selected a
single network – IL-6 signaling – for validation and out-
lined several molecular paths (as shown in Figure 1) that
accounted for the multifaceted up-regulation of IL-6 by
SMF that occurred over the first 1 to 3 days of exposure.
From the standpoint of disease intervention, the up-regu-
lation of IL-6 by SMF at first seems to be unwanted
because IL-6 is generally maintained at low levels in
healthy tissue [50]. Moreover, chronically elevated levels
of IL-6 are usually deleterious (for example, inflammation
and unabated astrocyte differentiation associated with
increased IL-6 experienced after brain or spinal cord injury
blocks axonal regeneration of neurons and thereby ham-
pers full recovery [35]). In some cases, however, the short-
term activation of IL-6 can be therapeutically beneficial;
for example, this pleiotropic cytokine can be neuroprotec-
tive immediately after injury [28]. Consequently, success-
ful therapeutic intervention involving IL-6 is contingent
upon transient – as experienced in the SMF-treated cells –
rather than on prolonged activation to avoid the deleteri-
ous consequences of chronic inflammation and other
long term consequences of sustained IL-6 production.
In a final set of experiments, we briefly investigated
whether SMF-mediated responses associated with IL-6 sig-
naling translated into changes in phenotype observable at
the whole cell level. Although IL-6 impacts numerous cell-
level and systemic responses, our experimental efforts
were focused by reports that IL-6 guides differentiation of
neural stem cells primarily to astrocytes [35]. These clues
led us to investigate whether evidence of astrocytogenesis
was seen in the hEBD LVEC cells, an embryonic line that
is predisposed to neural differentiation [24]. Interestingly,
responses consistent with differentiation (i.e., slowed pro-
liferation and morphological changes) were not reflected
in the biochemical markers indicative of the astrocyte dif-
ferentiation expected from IL-6. Instead, markers found in
oligodendrocyte precursor cells were manifest, indicating
that the other pathways modulated by SMF tuned the
'usual' activity of IL-6. Ultimately, if full oligodendrocyte
formation can be promoted in vivo by SMF without con-
Timeline of SMF-induced, IL-6 associated responses in hEBD LVEC cells Figure 11
Timeline of SMF-induced, IL-6 associated responses in hEBD LVEC cells. Data is compiled from experiments 
reported throughout this paper to show (A) early responses that occur within four hours of the start of continuous SMF expo-
sure, (B) intermediate responses that occur over the first day, and (C) longer term responses over the first week or so of SMF 
exposure. Data is shown for n ≥ 3 independent experiments and p < 0.05 for all data except for that indicated by "§" where p 
> 0.05 (these data were analyzed by SD but error bars are omitted from these graphs for clarity). All data shown – except for 
the proliferation data in Panel C that gives the reciprocal relationship – compares SMF-exposed to control cells with a value of 
100 as a baseline.BMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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comitant astrocyte enhancement (under the current
experimental conditions, full differential to oligodendro-
cytes was not feasible due to the absence of neurons and
other glial cells found in the in situ oligodendrocyte
microenvironment), this capability could lead to non-
invasive therapies for conditions such a multiple sclerosis
(MS) linked to oligodendrocyte pathologies.
Methods
Cell lines and culture conditions
The human embryoid body derived (hEBD) LVEC cell line
[24] was obtained from the Shamblott Laboratory (JHMI)
and was cultured in EGM2MV media (Clonetics, San
Diego, CA) that included 5.0% fetal bovine serum (FBS),
hydrocortisone, human basic fibroblast growth factor,
human vascular epidermal growth factor, R(3)-insulin-
like growth factor I, ascorbic acid, human epidermal
growth factor, heparin, gentamycin, and amphotericin.
The HEK AD293 line was obtained from the ATCC (Man-
assas, VA) and incubated in DMEM supplemented with
10% FBS under established conditions [72]. Cells were
cultured on tissue culture (T.C.) plastic coated with
bovine collagen I (Collaborative Biomedical Products,
Bedford, MA; 10 μg/cm2) in a water-saturated, 37°C incu-
bator with 5.0% CO2.
Exposure of cultured cells to SMF
Cell exposure to SMF was conducted for time intervals up
to a maximum of 9 days using a device obtained from the
Advanced Magnetic Research Institute, International
(AMRIi, Calgary, AB) that fit into a standard T. C. incuba-
tor with sufficient clearance on all sides so that incubator
functions (i.e., circulation of CO2 and water saturated air)
were not affected. The device was designed based on prin-
ciples derived from clinical testing of SMF (Diabetic
Peripheral Neuropathy (ClinicalTrials.gov Identifier:
NCT00134524) and Chronic Low Back Pain
(NCT00325377)) that the magnetic field must be unidi-
rectional with no reverse field passing through the sample
[73]. It was embedded with four 1" × 4" × 6" (inch) per-
manent neodymium (NdFeB) rectangular block magnets
with two located above and two below the central cavity
(Additional file 2: Figure S10). The device produced a field
with a magnetic flux gradient of < 1.0 mT/mm in the por-
tion of the central cavity where the cells were maintained
during experiments. This arrangement contrasts with
experimental set-ups where each well of a T. C. plate has
been supplied with SMF exposure by using a separate
magnet; in these cases (or in experiments specifically
designed to test gradient responses) the periphery of the
treatment areas were subject to much higher magnetic flux
gradients of 20, 21, or 28 mT/mm [31-33,74] that resulted
in different cellular responses than observed in the more
uniform portions of the magnetic fields.
As just explained, the SMF conditions used in the current
experiments were not expected to elicit gradient effects
because the gradient used was much shallower than previ-
ously reported (i.e., < 1.0 mT/mm compared to 20–28
mT/mm). Nevertheless, to ensure that gradient effects – or
other artefacts of the exposure conditions – did not
account for the effects observed in hEBD LVEC cells in this
study, several control experiments were conducted. First,
the direction of the flux (i.e., whether the device was ori-
ented upright so that the field was superimposed on the
Earth's magnetic field or oriented upside down so that the
applied field countered the background field) was tested
and found not to have an impact on the parameters under
investigation in hEBD LVEC cells. Second, differences in
field strength (i.e., whether the cells were exposed to field
at the extreme top or bottom of the treatment device when
six T. C. plates – the maximum capacity of the device –
were stacked on top of each other) did not measurably
affect the outcome of the experimental parameters
reported in this study. Finally, the orientation of the T. C.
plates (e.g., whether the plates were placed as shown in
Figure S10 (Additional file 2) or at 90°, 180°, or 270°
angles) did not alter experimental outcomes.
Despite the lack of variation in IL-6 related outcomes, the
experiments described in this report were always per-
formed with the induced static magnetic field superim-
posed in the same direction as the ambient field, the SMF-
treated cells were maintained in the central portion of the
device oriented as shown in Figure S10 (Additional file 2)
in the region the where magnetic flux density ranged
between 0.23 and 0.28 T (as measured by a gaussmeter,
Type 181002, Thyssen Magnet-und komponententech-
nik, Dortmund, Germany). Control cells were kept in an
identical incubator where the ambient magnetic field was
~52 μT (which was within 1 μT of the background levels
measured by us or reported by the National Geophysical
Data Center for the location where these experiments
were conducted (i.e., 52,359.0 nT at a latitude of 39° 19'
35" and a longitude of – 76° 36' 17",.
http:ngdc.noaa.gov/geomagmodels/
IGRFWMM.jsp?default Model=IGRF).
Transcriptional (mRNA) profiling
In all cases, the cells subjected to microarray profiling
were obtained from the same initial culture batch and
were subsequently cultured for a total of six days before
RNA was isolated and analyzed. Subconfluent (70%–
80%) undifferentiated hEBD LVEC (passage 11) cells were
trypsinized, resuspended, and replated at 5.0 × 105 cells in
10 ml medium in 10 cm T. C. dishes on "Day 0". All cells
were allowed to recover from the plating process by incu-
bating them under normal culture conditions for one day
after which time four conditions were investigated. For
Group 1, control cells were incubated for five additionalBMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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days under normal culture conditions. For Group 2, cells
were cultured under normal conditions for four addi-
tional days and then subjected to one day (~24 h) of SMF
exposure in the magnetic treatment device on "Day 6";
mRNA from these cells, as well as from the third group,
was isolated for analysis immediately after magnetic expo-
sure ended. For Group 3, cells were subjected to continu-
ous SMF exposure for five days. Finally, for Group 4, cells
were exposed to SMF for four days (from Day 2 through
Day 5) followed by a 24 h recovery period during which
time they were incubated under normal culture condi-
tions. mRNA was isolated from the cells and microarray
analysis was done using the Affymetrix Human Genome
U133 2.0 Plus Chip using the protocols and facilities
available through the Johns Hopkins Cancer Center
Microarray Core. All data was obtained in duplicate from
independent experiments. Software analysis was per-
formed using the Ingenuity Pathway tool (available
through the Microarray Core) using merged data from
each set of independent experiments. The microarry data
have been deposited in NCBI's Gene Expression Omnibus
[75] and are accessible through GEO Series accession
number GSE14474 http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE14474.
Calcium measurements
hEBD LVEC cells were incubated in Ca2+- and Mg2+-free
for PBS for up to four hours (longer time points decreased
cell viability making the assay results unreliable) with or
without SMF exposure. Intra- and extra-cellular calcium
levels were measured separately after the cells were sepa-
rated from their supernatants by pelleting with a 300 g, 2
min centrifugation step followed by lysis by sonication
with a GE130PB ultrasonic processor (General Electric,
New York, NY). Analysis of the supernatants and cell
lysates was then conducted using a calcium reagent set
(Pointe Scientific Inc., Canton, MI) and published meth-
ods [76].
Treatment of cells with exogenous gangliosides (GM3 and 
GD3)
The basic procedure for ganglioside supplementation fol-
lowed published procedures [77]. Briefly, cells were
plated in 6-well tissue culture dishes and incubated until
they reached 60% confluence. GM3 or GD3 (Matreya
LLC, Pleasant Gap, PA) was resuspended in serum-free
medium and briefly sonicated to ensure appropriate
micellar suspension and cellular incorporation of these
gangliosides. Cells were then incubated in culture
medium containing 1.0, 5.0, 10, 20, or 50 μM GM3 or
GD3 for varying periods of times (as specified in the
Results section and accompanying figures). In each case,
results were compared with a "solvent control," where an
equal volume of medium was added to cells without gan-
glioside.
Real-time PCR quantification of gene expression
The mRNA levelsofST3GAL5,  NEU3,  TLR4,  IL-
6andglyceraldehyde-3-phosphatedehydroge-
nase(GAPDH)wereanalyzedbyquantitativereal-timepolymer-
asechain  reaction (qRT-PCR) [77,78]. Primers (listed in
Table 6), were designed by using the Primer3 software
made available through the Broad Institute http://
genecruiser.broadinstitute.org/science/software and
obtained from MWG-Biotech (High Point, NC). The basic
protocol followed for qRT-PCR experiments began with
the isolation of total RNA from 5.0 × 106 cells with the
RNeasy Mini Kit (Qiagen, Valencia, CA) or by the TRIzol
(Invitrogen) method. RNA quality was assessed by agar-
ose gel electrophoresis (1.8% gels run with TAE buffer fol-
lowed by nucleic acid band visualization under UV
illumination after ethidium bromide staining) and quan-
tified by A260/A280 OD readings. RNA integrity was con-
firmed using 18 S rRNA primers, and samples were
standardized based on equal levels of β-actin cDNA.
Quantitative real-time PCR was performed in an ABI
Prism 7000 sequence detector (Applied Biosystems) using
SYBR Green PCR Master Mix reagent (Applied Biosys-
tems). Reactions were performed in 20 μl of a mixture
containing a 2.0 μl cDNA dilution, 1.0 μl (10 pmol/μl) of
primer, and 10 μl of 2× SYBR master mix containing
Amplitaq Gold DNA polymerase, reaction buffer, a dNTP
mixture with dUTP, passive reference, and the SYBR Green
I. qRT-PCR conditions were as follows: one cycle of 2.0
min at 50°C, 95°C for 10 min, followed by 40 cycles of
95°C for 15 s and 60°C for 1.0 min. Specific PCR prod-
ucts were detected with the fluorescent double-stranded
DNA binding dye, SYBR Green. qRT-PCR amplification
was performed in quadruplicate for each sample (typically
values for the replicates were within 2% of each other)
Table 6: Primers used for qRT-PCR
Gene Forward primer (5' to 3') Reverse primer (5' to 3')
ST3GAL5 CCC TGA ACC AGT TCG ATG TT CAT TGC TTG AAG CCA GTT GA
NEU3 CCT GAA GCC ACT GAT GGA A TTC CTG CCT GAC ACA ATC TG
IL-6 TAC ATC CTC GAC GGC ATC TC GCT ACA TTT GCC GAA GAG CC
TLR4 TGA GCA GTC GTG CTG GTA TC CAG GGC TTT TCT GAG TCG T
GAPDH GCA AAT TCC ATG GCA CCG T TCG CCC CAC TTG ATT TTG GBMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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and the results were replicated in at least three independ-
ent experiments. Gel electrophoresis and melting curve
analyses were performed to confirm correct PCR product
sizes and the absence of nonspecific bands. The expres-
sion level of each gene was normalized against β-actin
using the comparative CT method [79] according to the
manufacturer's protocols.
Analysis of cell surface and total levels of GM3 and GD3
The method used for the analysis of cell surface GM3 and
GD3 expression by flow cytometry was adapted from pub-
lished protocols [77]. Briefly, these tests were performed
by detaching hEBD LVEC cells by trypsinization and
washing them with washing buffer (1.0% bovine serum
albumin, 0.1% NaN3 in phosphate-buffered saline). Cells
(1.0 × 106) were stained with 20 μg/ml of a mouse mon-
oclonal antibody against GM3 (NBT-M101/M102, iso-
type IgM, clone M2590; Cosmo Bio Co., Ltd., Tokyo,
Japan) and detected with fluorescein isothiocyanate-con-
jugated Affinipure rabbit anti-mouse IgM (Jackson Immu-
noresearch, West Grove, PA). A similar procedure was
used for GD3 analysis, except cells were stained with
mouse anti-human ganglioside GD3 monoclonal anti-
body (Product number 371440, clone 110.14F9, isotype
IgG3; Calbiochem) diluted 1:50 in washing buffer and
detected with a donkey anti-mouse IgG antibody conju-
gated to fluorescein (Jackson Immunoresearch). Control
samples stained with secondary antibody alone were ana-
lyzed in parallel in each experiment. Samples were ana-
lyzed with a FACScan flow cytometer and Cell Quest
software (BD Immunocytometry Systems, San Diego,
CA), and a minimum of 5000 events were acquired for
each sample. Analysis of total (i.e., surface and intracellu-
lar) GM3 and GD3 was tested in fixed and permeabilized
cells [80] by adaptation of a method used to quantify
intracellular levels of p21WAF1 [81]. Briefly, before com-
pleting the staining procedure described above, cells were
fixed by incubation in 4.0% paraformaldehyde in phos-
phate-buffered saline for 10 min at room temperature fol-
lowed by
Western blot analyses
An equal amount of protein from each sample (20 μg)
was incubated for 5.0 min at 100°C in Laemmli buffer
(Bio-Rad), separated on a 7–11% SDS-polyacrylamide
discontinuous gel, and then electrophoretically trans-
ferred to a nitrocellulose membrane (Bio-Rad). The mem-
brane was blocked with Tris-buffered saline containing
5.0% nonfat milk and 0.1% Tween 20 for 1.0 h at room
temperature and then incubated overnight with rabbit
phospho-p44/42 MAPK (i.e., pERK1/2) monoclonal anti-
body and p44/42 MAPK (i.e., ERK1/2) antibody (1:1000
dilution) or phospho-p38 MAPK and p38 MAPK (1:2000)
or phospho-stat3 (Tyr705) and Stat3 rabbit antibody
(1:1000) (Cell Signaling Technology, Beverly, MA) at
4.0°C, followed by anti-rabbit or anti-mouse IgG, horse-
radish peroxidase-linked antibody (1:2000) for 1.0 h.
Bound antibody on the membrane was detected using the
SuperSignal West Dura Extended Duration Substrate
(Pierce) according to the protocols supplied by the manu-
facturer. Quantification of bands was performed by using
the NIH ImageJ software (available on the World Wide
Web at rsb.info.nih.gov/nih-image) following a pub-
lished method [82,83].
Measurement of proliferation with the MTT assay
For proliferation assays, control or SMF-exposed hEBD
LVEC cells were added to 96-well tissue culture plates at
3000 cells/well in serum-containing medium and cul-
tured for up to nine days with the culture medium replen-
ished every 3rd  day. To quantify cell proliferation by
measuring metabolic activity, 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, (Sigma) was
added to each well (0.5 mg/ml). After incubation for 3.0
h at 37°C, the supernatants were aspirated, and 100 μl of
n-propyl alcohol containing 0.1% Nonidet P-40 and 4.0
mM HCl were added. The colorimetric reaction was quan-
tified by using an automatic plate reader, μ Quant (Bio-tek
Instrument Inc., Winooski, VT) to measure absorbance at
570 nm with a reference filter of 690 nm. Each MTT assay
was carried out in triplicate. In all cases, measurement of
proliferation through cell counting by using a Coulter Z2
instrument (as described in our previous publications
[84]) yielded identical results.
Detection of apoptosis by Annexin V/propidium iodide 
assays
The Annexin V/propidium iodide flow cytometry method
was used for the detection and quantification of apoptosis
by following the procedure previously reported for Jurkat
cells [85,86] with the added step of trypsinizing the adher-
ent hEBD LVEC cells (the previously-tested Jurkat cells
grow in suspension and did not require this step). After
trypsinization and resuspension in complete medium,
cells were counted with a Coulter Z2 instrument, 1.0 × 106
cells from each sample were pelleted by centrifugation,
washed by gentle resuspension in Dulbecco's phosphate-
buffered saline, centrifuged again, and suspended in stain-
ing buffer. The cells were stained with fluorescein isothio-
cyanate-labeled Annexin V and propidium iodide and
analyzed by flow cytometry as described previously
[85,86].
Measurement of secreted IL-6 by ELISA
Cells were seeded in triplicate in a 96 well culture plate at
6000 cells/well in 200 μl of medium. After two days, cells
were exposed to SMF and supernatant was collected over
the time course indicated in the Results section and the
concentration of IL-6 was determined by an ELISA kitBMC Genomics 2009, 10:356 http://www.biomedcentral.com/1471-2164/10/356
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designed for this purpose (eBioscience, San Diego, CA)
following the protocol provided by the manufacturer.
Confocal imaging of Gal-C, GFAP, NEF and Vim
hEBD LVEC cells (1.0 × 105 in 2.0 ml of medium) were
plated on collagen coated 35 mm glass bottom dishes (35
mm, MatTek Corporation, Ashland, MA) and either
exposed to SMF during culture or subject to normal culti-
vation. On day 4 the monolayers were fixed in reagent A
and permeabilized in reagent B (Fix & Perm, Reagents A
and B, Caltag Laboratories, Burlingame, CA) followed by
washing with 3.0% BSA in PBS. Cells were incubated with
anti-galactocerebroside (Gal-C, 1:100) (Sigma, Saint
Louis, MO); anti-NEF 70 kD (1:100) (Chemicon, Temec-
ula, CA); anti-GFAP (1:100) (Santa Cruz, Los Angeles,
CA); or anti-vimentin (anti-Vim, 1:500) (BD Pharmingen,
San Diego, CA) for 2.0 h at RT. The secondary antibody
used to stain anti-GFAP, anti-NEF, and anti-Vim was Cy3-
conjugated Donkey anti-mouse IgG(H+L) and Cy3–con-
jugated Donkey anti-Rabbit IgG(H+L) was the secondary
anti-body used for anti-Gal-C (both were obtained from
Jackson ImmunoResearch Labs, West Grove, PA and used
at a 1:100). In all cases, a solution of the high-affinity
probe for F-actin Oregon Green® 488 phalloidin (1:100)
(Molecular Probes, now Invitrogen, Eugene, OR, Cat. No.
O7466) was added to the monolayers and incubated for
20 min and the monolayers were stained with nuclear-
localizing dye DAPI (1.0 μg/mL) for 10 min at RT. The
monolayers were then mounted using ProLong Gold®
anti-fade reagent (Molecular Probes, Eugene, OR, Cat.
No.P36934) and imaged by using a Zeiss 510 Meta confo-
cal microscope.
List of abbreviations
GD3: ganglioside GM3 (Neu5Acα3Galβ4GlcCer); GM3:
ganglioside GD3 (Neu5Acα8Neu5Acα3Galβ4GlcCer);
hEBD LVEC: the human embryoid body derived LVEC
cell line; IL-6: interleukin-6; LacCer: lactosylceramide
(Galβ4GlcCer); NEU3: neuramindase 3; qRT-PCR: quan-
titative real-time polymerase chain reaction; SD: standard
deviation;  SMF: static magnetic field(s); ST3GAL5:  β-
galactoside α-2,3-sialyltransferase 5; TLR4: toll-like recep-
tor 4.
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